GNFT
NASDAQGENFIT S.A.
Price$4.90+1.18 (+31.72%)
2025-08-192025-11-19
Latest news
25 items- SECSEC Form 15F-12B filed by GENFIT S.A.15F-12B - Genfit S.A. (0001757064) (Filer)
- SECSEC Form S-8 POS filed by GENFIT S.A.S-8 POS - Genfit S.A. (0001757064) (Filer)
- SECSEC Form RW filed by GENFIT S.A.RW - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 25 filed by GENFIT S.A.25 - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- ANALYSTH.C. Wainwright resumed coverage on Genfit with a new price targetH.C. Wainwright resumed coverage of Genfit with a rating of Buy and set a new price target of $9.00
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 20-F filed by GENFIT S.A.20-F - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
- SECSEC Form 6-K filed by GENFIT S.A.6-K - Genfit S.A. (0001757064) (Filer)
GNFT FAQ
7 questionsWhat does GENFIT S.A. do?
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in...Where does GNFT stock trade?
GENFIT S.A. (GNFT) is listed on NASDAQ.What sector and industry is GNFT in?
GENFIT S.A. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did GENFIT S.A. go public?
GENFIT S.A. (GNFT) completed its IPO in 2019.What are analysts saying about GNFT?
GENFIT S.A. has had 3 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $900.00 price target on 2025-08-19. Recent price targets range from $700.00 to $900.00.What companies are similar to GNFT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare GNFT side-by-side with any of them on Quantisnow.How can I track GNFT on Quantisnow?
Quantisnow aggregates GENFIT S.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GNFT to receive live email and push alerts on every new disclosure.